此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery

2012年9月13日 更新者:University of California, San Francisco

A Phase I/II Study of Fixed-Dose Rate Gemcitabine and Bevacizumab for Postoperative Adjuvant Treatment of Patients With Resected Pancreatic Cancer

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of pancreatic cancer by blocking blood flow to the tumor. Giving gemcitabine and bevacizumab after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase I/II trial is studying the side effects of gemcitabine and bevacizumab and to see how well they work in treating patients with pancreatic cancer that has been completely removed by surgery.

研究概览

详细说明

OBJECTIVES:

Primary

  • Determine the safety of adjuvant, fixed-dose rate gemcitabine hydrochloride and bevacizumab in patients with completely resected pancreatic cancer.
  • Determine the 1-year disease-free survival rate in patients treated with this regimen.

Secondary

  • Determine the 1- and 2-year overall survival rates in these patients.
  • Determine the median disease-free survival rate in these patients.
  • Determine the median overall survival rate in these patients.

OUTLINE: This is an open-label, non-randomized study.

Patients receive gemcitabine hydrochloride IV over 100 minutes followed by bevacizumab* IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease recurrence or unacceptable toxicity.

NOTE: *The first dose of bevacizumab is not administered until after 6 weeks have passed since surgery.

After completion of study therapy, patients are followed periodically for 18 months.

PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.

研究类型

介入性

注册 (预期的)

20

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • San Francisco、California、美国、94115
        • UCSF Helen Diller Family Comprehensive Cancer Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed adenocarcinoma of the pancreas

    • Completely resected disease

      • Underwent 1 of the following procedures 3-8 weeks ago:

        • Standard pancreaticoduodenectomy (for tumors of the pancreatic head)
        • Distal pancreatectomy (for tumors of the pancreatic tail)
      • No grossly positive surgical margins

        • Positive microscopic margins allowed
  • Nonmeasurable disease
  • No known CNS disease

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-1
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 6 months after completion of study therapy
  • CA 19-9 ≤ 2.5 times upper limit of normal (ULN)
  • Absolute neutrophil count ≥ 1,500/mm³
  • Hemoglobin ≥ 9 g/dL (transfusion or epoetin alfa allowed)
  • Platelet count ≥ 100,000/mm³
  • INR ≤ 1.5 (except in patients receiving full-dose warfarin)
  • Bilirubin ≤ 2.0 mg/dL
  • AST and ALT ≤ 2.5 times ULN
  • Creatinine ≤ 2.0 mg/dL
  • No clinically significant impairment of renal function
  • No postoperative complications, including any of the following:

    • Wound dehiscence or infection
    • Intra-abdominal abscess
    • Pancreatic or biliary leak or fistula
    • Grade 3 or 4 delayed hemorrhage (occurring > 5 days postoperatively)
    • Bowel perforation
  • No abdominal fistula, gastrointestinal perforation, or intra-abdominal abcess within the past 6 months
  • No history of major psychiatric disorder or other chronic medical illness that, in the opinion of the treating physician, contraindicates use of the study drugs or renders the patient at high risk of treatment-related complications
  • No other cancer within the past 5 years except basal cell or squamous cell skin cancer
  • No history of serious systemic disease, including any of the following:

    • Myocardial infarction or unstable angina within the past 12 months
    • New York Heart Association class II-IV congestive heart failure
    • Unstable symptomatic arrhythmia requiring medication

      • Chronic atrial arrhythmia (i.e., atrial fibrillation or paroxysmal supraventricular tachycardia) allowed
  • No history of stroke or transient ischemic attack
  • No symptomatic peripheral vascular disease
  • No significant vascular disease (e.g., aortic aneurysm, aortic dissection)
  • No inadequately controlled hypertension (i.e., blood pressure > 150/100 mm Hg on antihypertensive medication)
  • No prior hypertensive crisis or hypertensive encephalopathy
  • No proteinuria (defined as urine protein:creatinine ratio ≥ 1.0 OR proteinuria ≥ 2+ by dipstick urinalysis OR protein > 1 g by 24-hour urine collection)
  • No serious, nonhealing wound or ulcer
  • No evidence of bleeding diathesis or coagulopathy
  • No significant traumatic injury within the past 28 days

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No prior chemotherapy or radiotherapy for pancreatic cancer
  • No prior systemic or investigational therapy for pancreatic cancer
  • No major surgical procedure (except for resection of pancreatic cancer) or open biopsy within the past 28 days
  • No fine-needle aspiration or core biopsy within the past 7 days
  • No anticipated need for a major surgical procedure during study treatment
  • No concurrent newly prescribed nonsteroidal anti-inflammatory drugs (NSAIDs)

    • Concurrent chronic-dose NSAIDs for analgesia are allowed

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 屏蔽:无(打开标签)

研究衡量的是什么?

主要结果指标

结果测量
Safety of gemcitabine when administered with bevacizumab as assessed by NCI CTCAE v3.0
Disease-free survival rate at 1 year

次要结果测量

结果测量
Overall survival rate at 1 and 2 years
Median disease-free survival rate at 1 and 2 years
Median overall survival rate at 1 and 2 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Andrew Ko, MD、University of California, San Francisco

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2006年7月1日

初级完成 (实际的)

2007年10月1日

研究完成 (实际的)

2007年10月1日

研究注册日期

首次提交

2006年12月11日

首先提交符合 QC 标准的

2006年12月11日

首次发布 (估计)

2006年12月13日

研究记录更新

最后更新发布 (估计)

2012年9月17日

上次提交的符合 QC 标准的更新

2012年9月13日

最后验证

2012年9月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅